Tata 1mg revenue nears Rs 3,000 crore, loss narrows to Rs 287 crore

Tata 1mg closed FY26 with revenue of Rs 2,936 crore, up 23 percent from Rs 2,392 crore, and narrowed its consolidated net loss to Rs 287 crore.

The business runs through two entities. Tata 1mg Healthcare Solutions, the larger one, posted Rs 2,440 crore in revenue with a Rs 310 crore loss. Tata 1mg Technologies contributed Rs 496 crore in revenue and a Rs 23 crore profit. Total assets across the two stood at Rs 2,268 crore against liabilities of Rs 1,601 crore.

Parent Tata Digital grew revenue 12 percent to Rs 35,990 crore in FY26 with a net loss of Rs 4,974 crore and GMV of Rs 46,515 crore. Measured against that, 1mg is one of the healthier assets in the portfolio, growing faster than the parent while shrinking losses.

Context matters here. 1mg competes with Netmeds, PharmEasy and Apollo 24/7, but the sharper threat is quick commerce. Blinkit, Zepto and Instamart have all added over-the-counter and wellness lines to their dark stores, and pharmacy is a logical next step because basket frequency is high and margins beat staples.

For health and wellness brands the read is that the pure-play e-pharmacy channel is still compounding at 23 percent and is closer to sustainable economics, so it remains worth building on. But planning should assume demand splits. Over-the-counter products, supplements and personal care volume will keep migrating to dark stores, while prescription-linked and chronic refill volume stays with e-pharmacy platforms that hold licensed fulfilment. Build separate assortment and pack size logic for each channel instead of one shared catalogue.